ReportGem ReportGem 中文

REAL-TIME GLOBAL RESEARCH

Weekly Neurology Script Tracker: ACAD, AXSM, NBIX

Published: 2026-07-31Institution: Morgan StanleyCompany / ticker: ACAD.O,NBIX.O,AXSM.OPages: 16Original language: English

First-page research excerpt

Not for redistribution without written consent of Morgan Stanley

M

Update

July 31, 2026 03:51 PM GMT

Morgan Stanley & Co. LLC

Biotechnology | North America

Sean Laaman, Ph.D.

Equity Analyst

Weekly Neurology Script

Tracker: ACAD, AXSM, NBIX

Katherine Sun

Research Associate

Michael H Riad, Ph.D.

Research Associate

We highlight trends in IQVIA prescription data for select US

neurology products.

For the week ending Jul 24, total scripts for the US antipsychotic market grew

+2.7% Y/Y. Rolling 4-week total script (TRx) was +2.3% Y/Y and rolling 12-week TRx

was +2.3% Y/Y.

Natasha Arya

Research Associate

Biotechnology

North America

Industry View

Attractive

Sequential weekly TRx growth for antipsychotics was +1.3% w/w compared to 3.1%

the prior week. Exhibit 1 includes our basket of antipsychotics and

antidepressants, Exhibit 2 shows the launch trajectories for select antipsychotics,

and Exhibit 4 depicts TRx momentum over the last year. Exhibit 9 shows the

launch trajectories for select antidepressants. See inside for additional charts on key

trends.

Total scripts for bipolar depression medications1 grew +0.7% w/w. Rolling 4-week

TRx was +0.4% w/w. On a Y/Y basis, TRx grew +3.3% for the current week, +2.9%

for rolling 4-week, and +3.0% for rolling 12-week.

Acadia: Nuplazid for Parkinson's disease psychosis

• Weekly TRx grew 13% w/w, +14% Y/Y, and rolling 12-wk +6% Y/Y ( Exhibit 6 )

• New prescriptions (NRx) / TRx were 45% for the week

Axsome: Auvelity for major depressive disorder and agitation in Alzheimer's

dementia

• Weekly TRx grew +0% w/w, +34% Y/Y, and rolling 12-wk +33% Y/Y ( Exhibit

10 )

• New prescriptions (NRx) / TRx were 59% for the week

Neurocrine: Ingrezza for tardive dyskinesia and Huntington's disease chorea

• Weekly TRx grew 7% w/w, +19% Y/Y, and rolling 12-wk +21% Y/Y ( Exhibit 12 )

• New prescriptions (NRx) / TRx were 45% for the week

Momentum of top outpatient drugs :

Exhibit 1:

Notable drug total prescriptions (TRx). All figures are rounded to the

nearest hundred because IQVIA does not allow publication of exact Rx counts

~TRx / Week ending

Antipsychotics

Nuplazid (pimavanserin)

Caplyta (lumateperone)

Seroquel/XR (quetiapine /

quetiapine XR)

The excerpt is extracted automatically from page one and may contain layout or recognition errors. Sign in to review access options.

Open report viewer